EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Davi M Grecco iD, Luciano Araldi iD, Giordano C Soldera iD, João A B Zimmermann iD, João V Brisolara iD, Giovanna A Artero iD, Luiza F Streher iD, Maria E F Turatti iD, Harapan Harapan iD

Reviews in Medical Virology · 2026

DOI: 10.1002/rmv.70215 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Reviews in Medical Virology, 2026. Verfasst von Davi M Grecco und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil. Hauptthemen laut MEDLINE: Antiviral Agents, Mpox, Monkeypox. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tecovirimat has been widely used for the treatment of mpox despite limited evidence supporting its efficacy. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of tecovirimat for this purpose. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to June 5, 2026 for RCTs comparing tecovirimat with placebo or standard care in patients with laboratory‐confirmed mpox. Primary outcomes were time to clinical resolution of skin lesions, clinical resolution by day 28–29, and 28‐day all‐cause mortality. Hazard ratios (HRs) and risk ratios (RRs) were pooled using random‐effects models with restricted maximum likelihood estimation and Hartung–Knapp–Sidik–Jonkman adjustment. Risk of bias was assessed using RoB 2 and certainty of evidence using GRADE. Two low‐risk‐of‐bias RCTs involving 941 participants were included. Tecovirimat did not shorten the time to clinical resolution of skin lesions compared with placebo (HR 1.10, 95% CI 0.52–2.31, GRADE: moderate) or increase the lesion resolution by day 28–29 (RR 1.00, 95% CI 0.92–1.08, GRADE: high). No statistical heterogeneity was observed (I 2 = 0% for both outcomes). Mortality at day 28 was rare in both trials, precluding meta‐analysis. Virological clearance, pain‐related outcomes, and serious adverse events were also comparable between treatment groups. In conclusion, current randomized evidence does not support routine tecovirimat use to accelerate clinical recovery or improve mortality rates in patients with mpox, while further evidence is needed to determine whether selected high‐risk populations may benefit from antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsMpox, MonkeypoxHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

lesion resolutionmeta‐analysismonkeypoxtecovirimat

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
  • Department of Medicine, Universidade Nove de Julho (UNINOVE), São Paulo, São Paulo, Brazil.
  • Universidade Franciscana, Santa Maria, Rio Grande do Sul, Brazil.
  • Department of Medicine, Universidade do Planalto Catarinense (UNIPLAC), Lages, Santa Catarina, Brazil.
  • Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
  • Tropical Disease Center, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.

ORCID-Profile: Davi M Grecco, Luciano Araldi, Giordano C Soldera, João A B Zimmermann, João V Brisolara, Giovanna A Artero, Luiza F Streher, Maria E F Turatti, Harapan Harapan

Zitieren

APA

Grecco, D. M., Araldi, L., Soldera, G. C., Zimmermann, J. A. B., Brisolara, J. V., Artero, G. A., Streher, L. F., Turatti, M. E. F., & Harapan, H. (2026). Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70215

Vancouver

Grecco DM, Araldi L, Soldera GC, Zimmermann JAB, Brisolara JV, Artero GA, et al. Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70215

BibTeX
@article{Grecco2026,
  author = {Grecco, Davi M and Araldi, Luciano and Soldera, Giordano C and Zimmermann, João A B and Brisolara, João V and Artero, Giovanna A and Streher, Luiza F and Turatti, Maria E F and Harapan, Harapan},
  title = {Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Reviews in Medical Virology},
  year = {2026},
  doi = {10.1002/rmv.70215}
}
Kostenlos starten →